Literature DB >> 33893220

VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration.

Silas A Buck1,2, Briana R De Miranda3,4, Ryan W Logan5,6, Kenneth N Fish2, J Timothy Greenamyre3,7, Zachary Freyberg8,9.   

Abstract

Parkinson's disease (PD) is characterized by progressive dopamine (DA) neuron loss in the SNc. In contrast, DA neurons in the VTA are relatively protected from neurodegeneration, but the underlying mechanisms for this resilience remain poorly understood. Recent work suggests that expression of the vesicular glutamate transporter 2 (VGLUT2) selectively impacts midbrain DA neuron vulnerability. We investigated whether altered DA neuron VGLUT2 expression determines neuronal resilience in rats exposed to rotenone, a mitochondrial complex I inhibitor and toxicant model of PD. We discovered that VTA/SNc DA neurons that expressed VGLUT2 are more resilient to rotenone-induced DA neurodegeneration. Surprisingly, the density of neurons with detectable VGLUT2 expression in the VTA and SNc increases in response to rotenone. Furthermore, dopaminergic terminals within the NAc, where the majority of VGLUT2-expressing DA neurons project, exhibit greater resilience compared with DA terminals in the caudate/putamen. More broadly, VGLUT2-expressing terminals are protected throughout the striatum from rotenone-induced degeneration. Together, our data demonstrate that a distinct subpopulation of VGLUT2-expressing DA neurons are relatively protected from rotenone neurotoxicity. Rotenone-induced upregulation of the glutamatergic machinery in VTA and SNc neurons and their projections may be part of a broader neuroprotective mechanism. These findings offer a putative new target for neuronal resilience that can be manipulated to prevent toxicant-induced DA neurodegeneration in PD.SIGNIFICANCE STATEMENT Environmental exposures to pesticides contribute significantly to pathologic processes that culminate in Parkinson's disease (PD). The pesticide rotenone has been used to generate a PD model that replicates key features of the illness, including dopamine neurodegeneration. To date, longstanding questions remain: are there dopamine neuron subpopulations resilient to rotenone; and if so, what are the molecular determinants of this resilience? Here we show that the subpopulation of midbrain dopaminergic neurons that express the vesicular glutamate transporter 2 (VGLUT2) are more resilient to rotenone-induced neurodegeneration. Rotenone also upregulates VGLUT2 more broadly in the midbrain, suggesting that VGLUT2 expression generally confers increased resilience to rotenone. VGLUT2 may therefore be a new target for boosting neuronal resilience to prevent toxicant-induced DA neurodegeneration in PD.
Copyright © 2021 the authors.

Entities:  

Keywords:  VGLUT2; dopamine; glutamate; neurodegeneration; rotenone; tyrosine hydroxylase

Mesh:

Substances:

Year:  2021        PMID: 33893220      PMCID: PMC8260163          DOI: 10.1523/JNEUROSCI.2770-20.2021

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  73 in total

Review 1.  Alzheimer's disease and Parkinson's disease.

Authors:  Robert L Nussbaum; Christopher E Ellis
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 2.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

3.  Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.

Authors:  Alevtina Zharikov; Qing Bai; Briana R De Miranda; Amber Van Laar; J Timothy Greenamyre; Edward A Burton
Journal:  Neurobiol Dis       Date:  2019-01-15       Impact factor: 5.996

Review 4.  Toxin models of mitochondrial dysfunction in Parkinson's disease.

Authors:  Terina N Martinez; J Timothy Greenamyre
Journal:  Antioxid Redox Signal       Date:  2011-07-12       Impact factor: 8.401

5.  Sex Differences in Rotenone Sensitivity Reflect the Male-to-Female Ratio in Human Parkinson's Disease Incidence.

Authors:  Briana R De Miranda; Marco Fazzari; Emily M Rocha; Sandra Castro; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

6.  Glutamatergic and dopaminergic neurons in the mouse ventral tegmental area.

Authors:  Tsuyoshi Yamaguchi; Jia Qi; Hui-Ling Wang; Shiliang Zhang; Marisela Morales
Journal:  Eur J Neurosci       Date:  2015-01-09       Impact factor: 3.386

7.  Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro.

Authors:  Victor Tapias; J Timothy Greenamyre; Simon C Watkins
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

8.  Segregation of dopamine and glutamate release sites in dopamine neuron axons: regulation by striatal target cells.

Authors:  Guillaume M Fortin; Charles Ducrot; Nicolas Giguère; Willemieke M Kouwenhoven; Marie-Josée Bourque; Consiglia Pacelli; Rafael Koerich Varaschin; Marion Brill; Sherdeep Singh; Paul W Wiseman; Louis-Éric Trudeau
Journal:  FASEB J       Date:  2018-07-16       Impact factor: 5.191

9.  Acute action of rotenone on nigral dopaminergic neurons--involvement of reactive oxygen species and disruption of Ca2+ homeostasis.

Authors:  Peter S Freestone; Kenny K H Chung; Ezia Guatteo; Nicola B Mercuri; Louise F B Nicholson; Janusz Lipski
Journal:  Eur J Neurosci       Date:  2009-11-11       Impact factor: 3.386

10.  Functional Connectome Analysis of Dopamine Neuron Glutamatergic Connections in Forebrain Regions.

Authors:  Susana Mingote; Nao Chuhma; Sheila V Kusnoor; Bianca Field; Ariel Y Deutch; Stephen Rayport
Journal:  J Neurosci       Date:  2015-12-09       Impact factor: 6.167

View more
  6 in total

Review 1.  Sex Differences in Dopaminergic Vulnerability to Environmental Toxicants - Implications for Parkinson's Disease.

Authors:  Ashley Adamson; Silas A Buck; Zachary Freyberg; Briana R De Miranda
Journal:  Curr Environ Health Rep       Date:  2022-10-06

Review 2.  Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia.

Authors:  Silas A Buck; M Quincy Erickson-Oberg; Ryan W Logan; Zachary Freyberg
Journal:  Mol Psychiatry       Date:  2022-06-10       Impact factor: 13.437

3.  Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala.

Authors:  Liqiang Chen; Chetan Nagaraja; Samuel Daniels; Zoe A Fisk; Rachel Dvorak; Lindsay Meyerdirk; Jennifer A Steiner; Martha L Escobar Galvis; Michael X Henderson; Maxime W C Rousseaux; Patrik Brundin; Hong-Yuan Chu
Journal:  Elife       Date:  2022-07-01       Impact factor: 8.713

4.  Dopamine neurons exhibit emergent glutamatergic identity in Parkinson's disease.

Authors:  Thomas Steinkellner; William S Conrad; Imre Kovacs; Robert A Rissman; Edward B Lee; John Q Trojanowski; Zachary Freyberg; Subhojit Roy; Kelvin C Luk; Virginia M Lee; Thomas S Hnasko
Journal:  Brain       Date:  2022-04-29       Impact factor: 15.255

Review 5.  Roles of VGLUT2 and Dopamine/Glutamate Co-Transmission in Selective Vulnerability to Dopamine Neurodegeneration.

Authors:  Silas A Buck; M Quincy Erickson-Oberg; Sai H Bhatte; Chase D McKellar; Vishan P Ramanathan; Sophie A Rubin; Zachary Freyberg
Journal:  ACS Chem Neurosci       Date:  2022-01-07       Impact factor: 5.780

6.  Parkinson's disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2β), and NR4A2 (NURR1) in cortical neurons.

Authors:  Joseph Kochmanski; Nathan C Kuhn; Alison I Bernstein
Journal:  NPJ Parkinsons Dis       Date:  2022-09-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.